Back to Screener

Healthcare

Coeptis Therapeutics Holdings, Inc.(COEPW)

Live Price

Offline

$0.0104

+0.00% today

Window Change

-47.44%

Window

Jun 27, 2025 β†’ Apr 24, 2026

Market Cap
$64.72K
Revenue Growth
0.0%
EPS Growth
+50.3%
Dividend Yield
0.0%
Partial coverage

Historical coverage is still expanding

This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.

Coverage: 186 bars Β· Jun 27, 2025 β†’ Apr 24, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Coeptis Therapeutics Holdings, Inc. (COEPW) is a Healthcare stock with a market cap of $64.72K and listed on NASDAQ. The stock last traded around $0.01 and down 47.4% across the available one-year price window (Jun 27, 2025 β†’ Apr 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.3%, free cash flow -29.4% with operating margin -956.9% and ROIC -55.7%. Valuation already assumes a fairly strong business story at price/sales 42.3. Stock Foundry combines COEPW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

COEPW vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

COEPW

β€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

COEPW Max Drawdown

-78.90%

Trailing 1Y

SPY Max Drawdown

β€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for COEPW and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for COEPW

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.